BridgeBio Oncology Therapeutics (BBOT) is a pioneering biopharmaceutical company that employs an innovative 'moneyball for biotech' approach to accelerate the development of life-changing medicines for patients with rare diseases. Founded in 2015, BBOT pools early-stage research and projects from academia to minimize risk and foster innovation. The company is dedicated to pushing boundaries and empowering its team to tackle complex challenges in the biopharma industry. With a strong emphasis on ethical standards, collaboration, and the thoughtful use of AI, BridgeBio is committed to advancing patient care and redefining the future of medicine.